Ap­n­imed touts PhI­Ib da­ta for lead sleep ap­nea pro­gram, prepar­ing to ad­vance to piv­otal stud­ies

Not six months af­ter rais­ing cash to take a drug for ob­struc­tive sleep ap­nea through Phase III tri­als, Cam­bridge’s Ap­n­imed is set­ting the stage with a pos­i­tive read­out.

The biotech has been work­ing on oral can­di­date AD109 for ob­struc­tive sleep ap­nea, a sleep dis­or­der that has tra­di­tion­al­ly been treat­ed or mit­i­gat­ed with CPAP, where air is con­tin­u­al­ly pushed in­to pa­tient’s air­ways through a mask that has to be worn dur­ing sleep. How­ev­er, the biotech be­lieves AD109 might be the an­swer — and ini­tial re­sults from a Phase IIb study re­leased Mon­day are promis­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER